Radiomics: a Study of Outcome in Lung Cancer
Aim of the study: The main aim is to collect data of patients with lung cancer, and to perform different analyses on this data. The data contains information on patient and tumor characteristics, imaging, and treatment characteristics. With this data it is possible to improve and validate the predictive model for survival and long term toxicity in lung cancer by multicentric prospective data collection. The long term aim, beyond this specific study, is to build a Decision Support System based on the predictive models validated in this study. Hypothesis: The general hypothesis is that we get a better prediction in terms of AUC (area under the curve) of survival and long term toxicity when we combine multifactorial variables. These variables consist of information from clinical data, imaging data, data related to treatment type and treatment quality.
Checked against the public recordLast updated Mar 22, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Maastricht Radiation Oncology
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histological or cytological proven lung cancer (small cell or non-small cell); * 18 years or older; * Informed consent according to national rules (US: written informed consent, NL: no objection rule)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
- Gemelli Hospital Roma / Universita Cattolica del Sacre Cuore RomeRome
- Maastro clinic, University Hospital of MaastrichtMaastricht, Limburg
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 22, 2017. Always confirm current availability with the study team.